Search results for "Mach"

showing 10 items of 3360 documents

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer

2021

BackgroundThe prognosis of early breast cancer is linked to clinic-pathological stage and the molecular characteristics of intrinsic tumor cells. In some patients, the amount and quality of tumor-infiltrating immune cells appear to affect long term outcome. We aimed to propose a new tool to estimate immune infiltrate, and link these factors to patient prognosis according to breast cancer molecular subtypes.MethodsWe performed in silico analyses in more than 2800 early breast cancer transcriptomes with corresponding clinical annotations. We first developed a new gene expression deconvolution algorithm that accurately estimates the quantity of immune cell populations (tumor immune contexture,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMyeloid2435In silicoImmunologyCellbiostatisticsBreast NeoplasmsTranscriptome03 medical and health sciences0302 clinical medicineBreast cancerImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorImmunology and Allergytumor microenvironmentHumans1506Stage (cooking)RC254-282Neoplasm StagingPharmacologyClinical/Translational Cancer ImmunotherapyTumor microenvironmentbusiness.industryGene Expression ProfilingNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasePrognosisSurvival AnalysisGene Expression Regulation Neoplastic030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesistumor biomarkersMolecular MedicineFemalebusinessAlgorithmsUnsupervised Machine LearningJournal for Immunotherapy of Cancer
researchProduct

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy

2020

Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of1 year. Anti- programmed cell death protein 1 (anti-PD-1) monotherapy has demonstrated modest efficacy in previously treated GEA and ESCC. In 2020, four pivotal trials have established anti-PD-1 therapy as a new standard of care for selected GEA and ESCC patients as first-line advanced and adjuvant therapy. In this review, we discuss the recent results of the CheckMate 649, ATTRACTION-4, KEYNOTE-590 and CheckMate 577 trials. We consider these results in the context of current standards …

0301 basic medicineOncologymedicine.medical_specialty2019-20 coronavirus outbreakEsophageal Neoplasmsmedicine.medical_treatmentImmune checkpoint inhibitorsFirst lineAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineStomach NeoplasmsChemoimmunotherapyInternal medicinemedicineAdjuvant therapyHumansneoplasmsGastroesophageal adenocarcinomabusiness.industryHematologyImmunotherapyEsophageal cancermedicine.diseaseCombined Modality Therapydigestive system diseasesNivolumab030104 developmental biologyOncology030220 oncology & carcinogenesisbusinessAnnals of Oncology
researchProduct

New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin

2015

Oral fluoropyrimidines have been available for more than 10 years. Capecitabine is well established in treating solid tumors in Europe. S-1 (Teysuno®), an oral formulation containing the 5-fluorouracil (5-FU) prodrug tegafur and the two enzyme modulators gimeracil and oteracil, has not been available in non-Asia countries until recently. In Japan, S-1 in combination with cisplatin is the recommended first-line treatment in patients with gastric cancer. In Europe, the first trials with S-1 were disappointing due to high unacceptable incidences of adverse events. Pharmacokinetic studies showed differences in Asian and Caucasian patients; therefore, a new non-Asian study program was initiated,…

0301 basic medicineOncologymedicine.medical_specialtyAdministration OralAntineoplastic AgentsTegafurCapecitabine03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineDrug DiscoverymedicineClinical endpointHumansPharmacology (medical)Survival rateNeoplasm StagingPharmacologyCisplatinbusiness.industryCancerGeneral Medicinemedicine.diseaseHematologic DiseasesSurvival Rate030104 developmental biologyInfectious DiseasesOncologyTolerability030220 oncology & carcinogenesisDrug Therapy CombinationFluorouracilCisplatinbusinessmedicine.drugTegafur/gimeracil/oteracilChemotherapy
researchProduct

Asynchronous and pathological windows of implantation: two causes of recurrent implantation failure

2018

STUDY QUESTION: Is endometrial recurrent implantation failure (RIF) only a matter of an asynchronous (displaced) window of implantation (WOI), or could it also be a pathological (disrupted) WOI? SUMMARY ANSWER: Our predictive results demonstrate that both displaced and disrupted WOIs exist and can present independently or together in the same RIF patient. WHAT IS KNOWN ALREADY: Since 2002, many gene expression signatures associated with endometrial receptivity and RIF have been described. Endometrial transcriptomics prediction has been applied to the human WOI in two previous studies. One study describes endometrial RIF to be the result of a temporal displacement of the WOI. The other indic…

0301 basic medicineOncologymedicine.medical_specialtyConcordanceprecision medicineBiologyEndometrial tissue03 medical and health sciencesEndometrium0302 clinical medicineImplantation failuretranscriptomic predictorsInternal medicinemedicinepolycyclic compoundsHumansendometrial asynchronyEmbryo Implantationendometrial pathologyendometriumPathologicalRetrospective Studiesrecurrent implantation failure030219 obstetrics & reproductive medicineGene Expression ProfilingRehabilitationConfoundingObstetrics and GynecologyRetrospective cohort studyEmbryo TransferPenetranceGene expression profilinggene expression signatures030104 developmental biologyReproductive Medicinemachine learning predictorswindow of implantation displacementFemaleTranscriptomeInfertility Femaletranscriptomic taxonomy
researchProduct

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

2018

Abstract Background Standard treatment options for patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC) are associated with limited efficacy and some toxicity. Recently, immunotherapy with antibodies that inhibit the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) interaction has emerged as a new treatment option. This manuscript reviews early-phase and late-phase trials of immunotherapy in advanced GC/GEJC. Methods Searches for studies of immunotherapy in GC/GEJC were performed using PubMed, ClinicalTrials.gov, and abstract databases for select annual congresses. Findings were interpreted based on expert opinion. Results Monotherapy with anti–PD-1/PD-L1 …

0301 basic medicineOncologymedicine.medical_specialtyDurvalumabPhases of clinical researchPembrolizumabAvelumab03 medical and health sciences0302 clinical medicineAtezolizumabStomach NeoplasmsInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingNeoplasm Metastasisbusiness.industryStandard treatmentGeneral MedicineImmune checkpoint030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyNivolumabbusinessmedicine.drugCancer treatment reviews
researchProduct

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma

2019

Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several molecular classifications have been proposed, precision medicine for HER2-amplified GEA patients still represents a challenge. Despite improvement in clinical outcomes obtained by adding trastuzumab to first-line platinum-based chemotherapy, no other anti-HER2 agents used first-line or beyond progression have demonstrated any benefit. Several factors contribute to this failure. Among them, variable HER2 amplification assessment, tumour heterogeneity, molecular mechanisms of resistance and microenvironmental factors could limit the effecti…

0301 basic medicineOncologymedicine.medical_specialtyEsophageal NeoplasmsTumour heterogeneityReceptor ErbB-2DiseaseDrug resistanceAdenocarcinomaGastroesophageal Junction AdenocarcinomaGenetic Heterogeneity03 medical and health sciences0302 clinical medicineStomach NeoplasmsTrastuzumabInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansPrecision Medicineskin and connective tissue diseasesGastroesophageal adenocarcinomabusiness.industryGene AmplificationHematologyPrognosisPrecision medicineProgression-Free SurvivalBlockade030104 developmental biologyOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisEsophagogastric Junctionbusinessmedicine.drugAnnals of Oncology
researchProduct

64. EORTC-1203: Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: INNOVATION …

2016

0301 basic medicineOncologymedicine.medical_specialtybusiness.industryGeneral Medicinemedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTrastuzumab030220 oncology & carcinogenesisPerioperative chemotherapyInternal medicinemedicineSurgeryPertuzumabStomach cancerbusinessmedicine.drugEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Precision medicine in the adjuvant treatment of gastric cancer

2018

0301 basic medicineOncologymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancermedicine.diseasePrecision medicine03 medical and health sciences030104 developmental biology0302 clinical medicineText miningOncologyChemotherapy AdjuvantGastrectomyStomach Neoplasms030220 oncology & carcinogenesisInternal medicinemedicineHumansPrecision MedicinebusinessAdjuvantRetrospective StudiesThe Lancet Oncology
researchProduct

The effect of pre-cure bracket movement on shear bond strength during placement of orthodontic brackets, an in vitro study

2017

Background The purpose of this study was to determine the influence of linear and rotational pre-cure bracket displacement during the bonding procedure on shear bond strength (SBS) of orthodontic brackets. Material and Methods Stainless steel orthodontic premolar brackets were bonded to the buccal surfaces of 50 human pre-molars with a conventional two-step bonding protocol. Extracted human pre-molars were divided into 5 groups (n=10/group). In the Control Group, the brackets were bonded with no pre-cure bracket displacement or rotation. The Rotation Group was bonded with 45 degrees of pre-cure rotation. The Displacement Group was bonded with 2mm pre-cure linear displacement. The Rotation-D…

0301 basic medicineOrthodonticsUniversal testing machineMaterials scienceBracket:CIENCIAS MÉDICAS [UNESCO]Shear bond03 medical and health sciencesOrthodontic brackets030104 developmental biologymedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASPremolarmedicineIn vitro studySlippageGeneral DentistryRotation group SO
researchProduct

Malignant Rhabdoid Tumor in the Gastric Wall of an Aged Orangutan (Pongo pygmaeus)

1994

A 34-year-old female orangutan ( Pongo pygmaeus) developed renal failure and became uremic. At necropsy, large gastric masses were present around the cardia and in the corpus. Abdominal metastases occurred in the liver, pancreas, and right ovary. Light microscopic examination of the tumor revealed polygonal cells with vesicular nuclei and prominent nucleoli. The growth pattern was predominantly solid. Focal areas contained excentric cytoplasmic intermediate filament inclusions, as identified by immunohistochemistry and electron microscopy. Immunohisiochemical procedures demonstrated mainly the vimentin type of intermediate filaments. Except for occasional cytokeratin, other intermediate fil…

0301 basic medicinePathologymedicine.medical_specialty040301 veterinary sciencesVimentinHistogenesisBiologyMalignancy0403 veterinary science03 medical and health sciencesCytokeratinPongo pygmaeusStomach NeoplasmsPongo pygmaeusmedicineAnimalsVimentinIntermediate filamentRhabdoid TumorHistiocyteGeneral Veterinary04 agricultural and veterinary sciencesAnatomymedicine.diseaseApe DiseasesMicroscopy Electron030104 developmental biologybiology.proteinImmunohistochemistryFemaleVeterinary Pathology
researchProduct